
Brazil’s National Health Surveillance Agency (ANVISA) has moved to authorise Amryt’s Lojuxta (lomitapide) in the country as a treatment for …

Rare disease firm Amryt has announced interim efficacy data for its epidermolysis bullosa (EB) therapy AP101, showing that things are …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations

